New Zealand vs Spain: Pneumococcal conjugate second or third-dose vaccines (PCVc)
New Zealand
89.0%
in 2025
Spain
89.0%
in 2025
New Zealand rank
72nd
Spain rank
72nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- New Zealand
- Spain
How they compare
New Zealand currently reports 89.0% against 89.0% in Spain, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Spain ahead.
New Zealand ranks 72nd and Spain ranks 72nd of 194 countries.
Across the 3 decades both report, New Zealand averaged higher in 2 and Spain in 1.
Head to head by decade
| Decade | New Zealand | Spain | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 43.5% | 0.0% | 43.5% | New Zealand |
| 2010s | 92.6% | 27.8% | 64.8% | New Zealand |
| 2020s | 82.5% | 92.5% | 10.0% | Spain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), New Zealand or Spain?
- New Zealand, at 89.0% against 89.0% in Spain as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between New Zealand and Spain?
- 0.0%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Spain?
- 18 years are reported by both, from 2008 to 2025.
- How do New Zealand and Spain rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- New Zealand ranks 72nd and Spain ranks 72nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.